A study testing whether a GLP-1 medicine, semaglutide, can help people with chronic kidney disease protect their kidneys.

Who can join: Adults 18 to 84, have chronic kidney disease.
What you take: Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 3 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 4Sponsor Baylor Research InstituteDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 64

What this study is for

Primary condition: Chronic Kidney Disease. Also studied in: Type 2 Diabetes.

Full scientific study title: Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD).

Who can join

Age18 to 84SexAny

Adults 18 to 84, have chronic kidney disease. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Patients aged 18-84 years
eGFR 45 to ≤90 mL/min/1.73 m2
UACR \>200 mg/g
diagnosis of T2D
receiving ≤2 guideline-recommended drug classes irrespective of dose for ≥4 weeks prior to screening

Key exclusion criteria

Type 1 diabetes
any known primary non-diabetic kidney disease (i.e., polycystic kidney disease, glomerulonephritis, interstitial nephritis, etc.)
history of kidney transplant
liver disease (i.e., aspartate transaminase or alanine transaminase \>5 times, or bilirubin \>3 times the upper limit of normal)
serum potassium \>5.5 mEq/L at baseline

Where this trial runs

This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.

Texas1 site

Baylor Scott and White Medical Center- Temple
Temple, Texas
Shahzeb Khan, MD469-326-2636shahzeb.khan@bswhealth.org

Follow this trial

We email you if NCT07547878 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Scheduled start: April 30, 2026. Expected completion: March 31, 2029. Last updated on ClinicalTrials.gov: May 8, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.